Delhi Police Crime Branch and the Delhi Drugs Control Department seize a batch of Abhayrab rabies vaccine after it is declared misbranded and not of Standard Quality by the Central Drugs Laboratory (CDL), Kasauli. The batch is identified as KE25012, and officials report that the seizure follows findings tied to the vaccine’s lab assessment.
India Today and Mint both cite statements from India’s drug regulator, the DCGI, indicating that regulatory action is taken based on the central laboratory’s classification. Mint adds that DCGI says no part of the batch has been exported to any other country. The reported focus across outlets is the misbranding designation, the role of the CDL in arriving at the quality determination, and the involvement of Delhi authorities in the seizure.
The outlets largely align on what is seized, the lab’s finding, and the regulator’s position on export status. Differences are limited to the framing and emphasis on which agencies were involved and what the DCGI specifically states in response to the incident.
